CD19 and neoplasm: As the same molecular biomarkers can be expressed in some normal tissues or organs, especially the lymphatic tissues, CAR-T cell therapy can destroy normal tissues referred to as on-target/off-tumor toxicity, e.g., B cell aplasia in anti-CD19/20 CAR-T cell treatment [3].